David A. Siegel Cognition Therapeutics Inc Transaction History

Two Sigma Advisers, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.45 $18,750 - $43,125	-12,500 Reduced 44.48%	15,600 $33,000
Q1 2022 May 16, 2022	SELL	$2.41 - $6.9 $98,328 - $281,520	-40,800 Reduced 59.22%	28,100 $77,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $12.98 $351,390 - $894,322	68,900 New	68,900 $435,000

9.4M

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $43.4M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.